Status:
NOT_YET_RECRUITING
Impact of NMN Supplementation on CD4+ T Cell Recovery in HIV Patients With Immunological Failure
Lead Sponsor:
TriHealth Inc.
Collaborating Sponsors:
DoNotAge.org
Conditions:
Human Immunodeficiency Virus
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This proof-of-concept study aims to investigate the potential impact of supplementing with Nicotinamide Mononucleotide (NMN), a direct precursor of NAD+ on CD4+ T cell recovery in virologically suppre...
Eligibility Criteria
Inclusion
- HIV-infected adults aged 18 years or older
- Virologically suppressed on ART documented with two negative viral loads separated by at least 6 months
- Confirmed diagnosis of immunological failure (CD4+ T cell count \<350 cells/µL 2 years after effective ART initiation)
- Willing to provide informed consent
Exclusion
- Active opportunistic infections
- Known allergies or sensitivities to NMN or any components of the NMN supplement
- Current or recent use of other supplements or medications known to affect NAD+ metabolism (Niacin, NR, NMNH, etc.)
- Pregnancy or breastfeeding
- Significant liver or kidney disease
- Active malignancy
- History of uncontrolled substance abuse
- Severe medical conditions that might interfere with study participation
- Unable to consent
Key Trial Info
Start Date :
April 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2025
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT06889142
Start Date
April 1 2025
End Date
July 1 2025
Last Update
April 3 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.